When does Basilea report earnings and how does it affect BSLN.SW stock?

Basilea reports on **17 Feb 2026**. Earnings will affect BSLN.SW stock through revenue and margin updates for Cresemba and commentary on pipeline trials; positive guidance could drive shares higher while weaker numbers could prompt a pullback.

What are key valuation metrics to watch for BSLN.SW stock?

Key metrics include PE **10.60**, EPS **5.48**, price/book **7.04**, free cash flow yield **9.34%**, and cash per share **10.27**. Compare these to Healthcare peers to gauge relative value.

What is Meyka AI's short-term forecast for BSLN.SW stock?

Meyka AI's forecast model projects a monthly price of **CHF63.02**, a yearly projection of **CHF54.32**, and a three-year projection of **CHF64.26**. These are model-based projections and not guarantees.

What are the main risks investors should consider for BSLN.SW stock?

Primary risks are clinical trial delays or failures, weaker product sales for Cresemba or Zevtera, regulatory setbacks, and short-term volatility around the **17 Feb 2026** earnings release.

CH Stocks

BSLN.SW Basilea (SIX) CHF57.00 after hours 13 Feb 2026: earnings 17 Feb may set tone

ByHuzaifa Zahoor February 13, 2026

BSLN.SW stock trades at CHF57.00 in after-hours trade on 13 Feb 2026, a decline of -1.55% on the day as investors position ahead of Basilea Pharmaceutica AG’s earnings on 17 Feb 2026. The company reports a trailing EPS of 5.48 and a PE of 10.60, below the Healthcare sector multiple. With product sales from Cresemba and pipeline readouts for derazantinib and lisavanbulin, earnings and guidance will likely drive short-term volatility and reprice valuation.